Skip to content

#LSD

  1. STAT: psychedelics78

    Definium says LSD therapy DT120 eased anxiety in second late-stage trial

    Definium Therapeutics said its LSD therapy DT120 helped patients with anxiety in a second late-stage trial.

    Why it matters: The reported 5.1-point gap between DT120 and placebo mirrors the company's first late-stage anxiety study, so the pending regulatory filing will test whether that effect size holds up in a review.

  1. STAT: psychedelics83

    Definium says LSD therapy DT120 helped major depression in first Phase 3 trial

    Definium Therapeutics said on Monday that its LSD therapy DT120 significantly helped patients with major depression in its first Phase 3 trial. Six weeks after a single dose.

    Why it matters: The topline gives the first Phase 3 readout for an LSD-based depression treatment, so the size of the placebo gap and the waning at 12 weeks are the numbers that will shape the next regulatory step.

You have reached the end